• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treat

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    Merck KGaA, Quris-AI Expand Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treat

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treat

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC

    Sartorius, SPARTA Biodiscovery Partner on Nanoparticle Analysis Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Societal CDMO

    TaiMed Biologics

    Quotient Sciences

    INCOG BioPharma Services

    Federal Equipment Company
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Societal CDMO

    TaiMed Biologics

    Quotient Sciences

    INCOG BioPharma Services

    Federal Equipment Company
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Biotechnology’s Role in Improving Stroke Outcomes

    The biotechnology sector is investigating the role of neural plasticity to treat the damage caused by stroke.

    Biotechnology’s Role in Improving Stroke Outcomes
    Paul Brennan, President and CEO, NervGen Pharma Corp.07.11.22
    A stroke is a condition where central nervous system (CNS) tissue is destroyed due to lack of blood flow and oxygenation to part of the brain. As a result of damaged neural pathways, patients experience loss of function with the disease manifestation dependent upon which region of the brain is affected. Stroke either significantly impairs the flow of blood to the brain (ischemic stroke) or it involves the rupture of blood vessels in the brain (hemorrhagic stroke). In either case, the result is the mass death of neurons which short-circuits the central nervous system (Figure 1).


    Figure 1: Ischemic and Hemorrhagic Stroke
    Both types of strokes can result in substantial and debilitating loss of movement, senses, vision, language, speech, balance, difficulty with coordination and walking, and cognition. During an ischemic stroke, there is a mass die-off of brain cells amounting to around two million brain cells perishing every minute post-injury.

    According to a report published by the World Stroke Organization in 2022, there are over 12 million new strokes each year, and there are over 100 million people currently living who have previously experienced a stroke. Of the new strokes that occur globally each year, ischemic stroke affected 7.6 million people, or about 62% of the total population who experience stroke, and hemorrhagic stroke afflicted 4.6 million, or 38% of the total population who experience stroke. For the U.S., the Center for Disease Control and Prevention (CDC) reports that every year over 795,000 people in the U.S. have a stroke, of which approximately 76% are first time strokes.1 Interestingly, the incidence of ischemic stroke appears to be much higher in the U.S. with 87% of all strokes classified as ischemic strokes.

    Of the approximately 795,000 people in the U.S. who suffer a stroke each year, only about 10% of them return to life as it was before. However, 20% of people who suffer a stroke die within a week, while another 13% die within the first year. Stroke is a leading cause of serious long-term disability and reduces mobility in more than half of stroke survivors age 65 and over.

    Additionally, stroke related costs in the U.S. alone, were estimated by the CDC to be $46 billion between 2014 and 2015 (the latest figures available), a toll growing as the size of the aged population continues to expand.

    Currently there is only one treatment approved for stroke, called Alteplase, or tissue plasminogen activator (tPA). Alteplase is a clot buster, and thus can only be used in patients with an ischemic stroke, which must be first confirmed by imaging. According to the FDA approved labelling, Alteplase must be administered within 3 hours of a stroke. Due to the time restrictions for starting treatment and the requirement for a brain imaging study prior to treatment, tPA is only administered to approximately 5% of patients suffering from a stroke. A key takeaway here is that no drug has ever before been approved anywhere in the world to repair or restore damage from a stroke. 

    Role of brain plasticity to treat stroke

    Today, the approximately 100 million stroke survivors globally have no drug treatments available to repair the damage that stroke causes. The biotechnology sector is investigating the role of neural plasticity to treat the damage caused by stroke. Improving plasticity, which repairs CNS damage, can have significant impact across multiple neurological functions, including motor and sensory. Frontiers in Cellular Neurosciences defines “neural plasticity, also known as neuroplasticity or brain plasticity, as the ability of the nervous system to change its activity in response to intrinsic or extrinsic stimuli by reorganizing its structure, functions or connections.”2

    The ability to enhance plasticity is not only relevant to stroke, but also to any condition where there is damage to CNS tissue. Enhancing plasticity results from “axonal sprouting,” the process of fine nerves processing—sprouting—from the intact axons to reinnervate denervated muscle fibers. Increased plasticity (axonal sprouting) results in the creation of new neural connections and increased production of adult neuronal stem cells with enhanced migration of these cells to the site of damage.

    “The ability to enable plasticity is relevant to any condition where there is central nervous system damage including Alzheimer’s disease, traumatic brain injury, spinal cord injury and multiple sclerosis,” said Dr. Jerry Silver at Case Western Reserve University who discovered a novel peptide-based innovation—NVG-291.

    Dr. Silver discovered a class of molecules, called chondroitin sulfate proteoglycans (CSPGs), that are upregulated in response to nervous system damage and that inhibit repair. NVG-291 was designed to modulate the inhibitory effect of CSPGs, thereby enhancing the body’s natural repair mechanisms, including plasticity, regeneration and remyelination.

    “NVG-291 offers a potential new treatment paradigm for stroke by enabling repair of the damage caused rather than trying to limit or contain the extent of the damage,” said Dr. Silver.

    Stroke patients often face motor, sensory, spatial learning and memory function deficits.  Studying the role that plasticity treatment in the treatment of stroke patients to improve these functional deficits offers the potential for a completely new treatment paradigm. 

    Current therapy focuses on restoring blood flow to the affected area as soon as possible in the first hours after the stroke. In contrast this potential new treatment for stroke could enable repair of damage caused by stroke rather than trying to limit or contain the extent of the damage. The ability to promote plasticity, either by promoting axonal sprouting or the migration of adult neural stem cells to repair CNS damage is a revolutionary development which would lead to a change in the treatment paradigm for stroke, while also providing a treatment option to millions of stroke victims. 

    References
    1. https://www.cdc.gov/stroke/facts.htm#:~:text=Every%20year%2C%20more%20than%20795%2C000,are%20first%20or%20new%20strokes.&text=About%20185%2C000%20strokes%E2%80%94nearly%201,have%20had%20a%20previous%20stroke.&text=About%2087%25%20of%20all%20strokes,to%20the%20brain%20is%20blocked
    2. https://www.frontiersin.org/articles/10.3389/fncel.2019.00066/full#:~:text=Neural%20plasticity%2C%20also%20known%20as,structure%2C%20functions%2C%20or%20connections


    Paul Brennan is President and Chief Executive Officer of NervGen Pharma Corp., a publicly traded clinical stage biotech company dedicated to discovering and developing treatments for nervous system damage due to injury or disease. He can be reached at pbrennan@nervgen.com; www.Nervgen.com
      Loading, Please Wait..
      Breaking News
      • Univercells Expands into the U.S. With New Offices in Andover, MA
      • Evecxia Therapeutics, Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treat
      • Sanner Group Opens Second Manufacturing Facility in China
      • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
      • Merck KGaA, Quris-AI Expand Collaboration
      View Breaking News >
      CURRENT ISSUE

      September 2023

      • Pharma Supply Chains: From Fragile to Agile
      • Overcoming Stressors in Knowledge Transfer
      • Innovations in Pharma Packaging
      • HPAPI Manufacturing Trends
      • Sustainable Packaging in Pharma: No Longer a Pipe Dream
      • Revolutionizing Pharma’s Supply Chain
      • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
      • Solving Pharma’s Underlying Rebate Leakage Problem
      • Advanced Manufacturing and a Roadmap to the Facility of the Future
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
      Natrol Launches First Non-Melatonin Sleep Supplement
      Metagenics Releases Consumer Survey on Menopausal Support Supplement
      Coatings World

      Latest Breaking News From Coatings World

      California Sports Surfaces Celebrates 70 Years
      ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
      AkzoNobel Shares Sustainable Architectural Solutions at Conference
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
      SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
      ResMed, Nyxoah Team Up to Grow Sleep Apnea Awareness & Therapy in Germany
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Univercells Expands into the U.S. With New Offices in Andover, MA
      Evecxia Therapeutics, Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treat
      Sanner Group Opens Second Manufacturing Facility in China
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
      74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
      Stoelzle Glass Group Names New CEO
      Happi

      Latest Breaking News From Happi

      The Estée Lauder Companies Launches 2023 Breast Cancer Campaign
      BASF Personal Care Introduces New Cosmetic Ingredient
      Breakfast with Oral Care Benefits?
      Ink World

      Latest Breaking News From Ink World

      Siegwerk’s Climate Targets Validated by SBTi
      ROSS Offering Cost-Effective, Expertly Reconditioned Equipment
      Amcor plc Adds Lucrèce Foufopoulos-De Ridder to Board of Directors
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      SABIC and partners launch bio-based IML solution for food packaging
      tesa completes expansion of Michigan manufacturing facility
      Comexi and Asahi to host 'Effortless Platemaking' event
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Greentech Introduces Air Filter with Advanced Odor Elimination
      Ontex Divests Pakistan Operations to ASAIA Holding
      Goodnites Bedwetting Underwear Recognized by Good Housekeeping
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
      ChitogenX Granted New U.S., Canadian ORTHO-R Patent
      Centinel Spine prodisc System Surpasses 2,500-Implant Milestone
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
      Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More
      SCHOTT Strengthens Glass Substrate Portfolio

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login